Gurgaon-based Ranbaxy Laboratories Ltd has launched a generic version of Prasugrel in India. The product called Prasita is an antiplatelet agent for prevention of atherothrombotic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Prasita is solely marketed by Ranbaxy in India.
Following the April 2009 launch of Olvance (olmesartan medoxomil), an antihypertensive originally discovered by Tokyo-based Daiichi Sankyo Company Ltd, Prasita is the second product from the Daiichi Sankyo portfolio to be introduced in India through the Ranbaxy business network. Ranbaxy will create awareness, understanding and acceptance of the new antiplatelet therapy among the target audiences in the country.
On Thursday, Ranbaxy's shares ended 1.34% up at Rs424 on the Bombay Stock Exchange, while the benchmark Sensex closed 1.59% up at 16,922 points.
The Chennai-based generic pharma major, Orchid Chemicals & Pharmaceuticals Ltd has entered an agreement to acquire Karalex Pharma, a US-based generic marketing and sales service company, through an all-cash deal for an undisclosed amount. The transaction is expected to close by this month subject to customary closing conditions. Through this acquisition, Orchid has created its presence in the front-end US market and will be able to reach its generic products to the US customers directly.
Headquartered in New Jersey, Karalex Pharma is a leading provider of generic pharmaceuticals focused exclusively on the US healthcare market. Orchid is a leading pharmaceutical company involved in the development, manufacture and marketing of diverse bulk actives, formulations and nutraceuticals.
On Thursday, Orchid's shares ended 4.61% up at Rs151 on the Bombay Stock Exchange, while the benchmark Sensex closed 1.59% up at 16,922 points.
The holy cows of our corporate world do not want the proposed minimum 25% public float norms to...